Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K on 20-Feb-2014All Recent SEC Filings

Show all filings for THERAVANCE INC

Form 8-K for THERAVANCE INC


20-Feb-2014

Regulation FD Disclosure


Item 7.01. Regulation FD Disclosure

The information contained in this Item 7.01 and in the accompanying exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On February 20, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. issued a press release announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use issued an opinion for umeclidinium/vilanterol (UMEC/VI) under the proposed brand name ANORO(R). ANORO(R) is a combination of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a long-acting beta2 agonist (LABA) in a single inhaler, the ELLIPTA(R). UMEC/VI has been developed under the LABA collaboration agreement between Glaxo Group Limited and Theravance, Inc. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits

(d) Exhibits
99.1 Press Release dated February 20, 2014


  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.